Literature DB >> 19714572

Tolerance checkpoints in B-cell development: Johnny B good.

Roxane Tussiwand1, Nabil Bosco, Rhodri Ceredig, Antonius G Rolink.   

Abstract

B-cell development up to the immature B-cell stage takes place in the bone marrow, while final maturation into mature B cells occurs in the spleen. During differentiation, the precursor and immature B cells have to pass several checkpoints, including those in which they are censored for being auto-reactive, and therefore being potentially dangerous. Numerous studies have shown that the immature B-cell stage in the bone marrow and the transitional B-cell stages in the spleen comprise distinct checkpoints at which auto-reactivity is censored. Recently, evidence has been provided that the large pre-BII stage in the bone marrow, at which the pre-BCR is expressed, is yet another B-cell tolerance checkpoint. Here, we review these findings and speculate on directions for possible further experimentation.

Entities:  

Mesh:

Year:  2009        PMID: 19714572     DOI: 10.1002/eji.200939633

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

Review 1.  Microparticles as autoadjuvants in the pathogenesis of SLE.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  CXCL13 responsiveness but not CXCR5 expression by late transitional B cells initiates splenic white pulp formation.

Authors:  Harold R Neely; Martin F Flajnik
Journal:  J Immunol       Date:  2015-02-06       Impact factor: 5.422

3.  ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.

Authors:  H Elizabeth Broome; Laura Z Rassenti; Huan-You Wang; Lilly M Meyer; Thomas J Kipps
Journal:  Leuk Res       Date:  2011-08-02       Impact factor: 3.156

4.  Absence of surrogate light chain results in spontaneous autoreactive germinal centres expanding V(H)81X-expressing B cells.

Authors:  Ola Grimsholm; Weicheng Ren; Angelina I Bernardi; Haixia Chen; Giljun Park; Alessandro Camponeschi; Dongfeng Chen; Berglind Bergmann; Nina Höök; Sofia Andersson; Anneli Strömberg; Inger Gjertsson; Susanna Cardell; Ulf Yrlid; Alessandra De Riva; Inga-Lill Mårtensson
Journal:  Nat Commun       Date:  2015-05-11       Impact factor: 14.919

Review 5.  Tonic Signals: Why Do Lymphocytes Bother?

Authors:  Darienne R Myers; Julie Zikherman; Jeroen P Roose
Journal:  Trends Immunol       Date:  2017-07-25       Impact factor: 16.687

6.  Elevated BCR signaling and decreased survival of Lyn-deficient transitional and follicular B cells.

Authors:  Andrew J Gross; Irina Proekt; Anthony L DeFranco
Journal:  Eur J Immunol       Date:  2011-11-10       Impact factor: 5.532

7.  Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant.

Authors:  Tania Habib; Andrew Funk; Mary Rieck; Archana Brahmandam; Xuezhi Dai; Anil K Panigrahi; Eline T Luning Prak; Almut Meyer-Bahlburg; Srinath Sanda; Carla Greenbaum; David J Rawlings; Jane H Buckner
Journal:  J Immunol       Date:  2011-11-21       Impact factor: 5.422

Review 8.  N-3 polyunsaturated fatty acids modulate B cell activity in pre-clinical models: Implications for the immune response to infections.

Authors:  Jarrett Whelan; Kymberly M Gowdy; Saame Raza Shaikh
Journal:  Eur J Pharmacol       Date:  2015-05-27       Impact factor: 4.432

Review 9.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Activation of rheumatoid factor-specific B cells is antigen dependent and occurs preferentially outside of germinal centers in the lupus-prone NZM2410 mouse model.

Authors:  Allison Sang; Haitao Niu; Jaime Cullen; Seung Chul Choi; Ying Yi Zheng; Haowei Wang; Mark J Shlomchik; Laurence Morel
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.